Literature DB >> 4974510

Trimethoprim in the treatment of urinary infections in hospital.

R N Grüneberg, R Kolbe.   

Abstract

Success in the cure of urinary infections of hospital patients was compared for five-day courses of sulphamethoxazole alone, sulphamethoxazole plus one-tenth its weight of trimethoprim, and sulphamethoxazole plus one-fifth its weight of trimethoprim (Septrin). The cure rates were 65%, 84%, and 92% respectively. Fifty-four per cent. of 111 patients had urinary tract abnormalities. Forty-three per cent. of the causative organisms were sulphonamide-resistant in vitro. There were no major side-effects, though two patients had pruritus or a rash.The degree of potentiation of sulphamethoxazole activity by one-fifth the weight of trimethoprim was so great that its cure rate of infections due to sulphonamide-resistant organisms exceeded that of sulphamethoxazole alone used in infections due to sulphonamide-sensitive organisms. The degree of synergism between trimethoprim and sulphamethoxazole demonstrated in vitro against urinary organisms was directly related to the cure rate of the combination.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4974510      PMCID: PMC1982262          DOI: 10.1136/bmj.1.5643.545

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  5-BENZYL-2,4-DIAMINOPYRIMIDINES AS ANTIBACTERIAL AGENTS. I. SYNTHESIS AND ANTIBACTERIAL ACTIVITY IN VITRO.

Authors:  B ROTH; E A FALCO; G H HITCHINGS; S R BUSHBY
Journal:  J Med Pharm Chem       Date:  1962-11

2.  [TRIAL TREATMENT OF VARIOUS "PROTEUS" INFECTIONS WITH 2,4-DIAMINO-5-(3,4,5-TRIMETHOXYBENZYL) PYRIMIDINE, OR (TRIM'ETHOPRIME)].

Authors:  M SCHNEIDER; L SCHWARZENBERG; A CATTAN; J R SCHLUMBERGER; J L AMIEL; G MATHE
Journal:  Presse Med       Date:  1965-03-27       Impact factor: 1.228

3.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

4.  Single-dose treatment of acute urinary tract infection: a controlled trial.

Authors:  R N Grüneberg; W Brumfitt
Journal:  Br Med J       Date:  1967-09-09

5.  Trimethoprim: laboratory and clinical studies.

Authors:  J H Darrell; L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1968-03       Impact factor: 3.411

  5 in total
  24 in total

Review 1.  Antibacterial drugs today. I.

Authors:  A P Ball; J A Gray; J M Murdoch
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  The choice of anti-microbial therapy in urinary infections in children.

Authors:  H Saxena; D Mehrotra; M Sharma
Journal:  Indian J Pediatr       Date:  1975-12       Impact factor: 1.967

3.  Sulphadimidine, co-trimoxazole, and a placebo in the management of symptomatic urinary tract infection in general practice.

Authors:  D Brooks; G Garrett; R Hollihead
Journal:  J R Coll Gen Pract       Date:  1972-10

4.  A double-blind cross-over trial of trimethoprim and sulphamethoxazole in chronic bronchitis.

Authors:  I W Webster
Journal:  Thorax       Date:  1971-05       Impact factor: 9.139

5.  Short-term treatment of patients with chronic and recurrent urinary tract infections with co-trimoxazole.

Authors:  H J de Voogt; H Mattie
Journal:  Urol Res       Date:  1973-12

6.  Sulphamethoxazole-trimethoprim: the first two years.

Authors:  D S Reeves
Journal:  J Clin Pathol       Date:  1971-07       Impact factor: 3.411

7.  Neonatal meningitis treated with trimethoprim and sulphamethoxazole.

Authors:  R N Morzaria; I G Walton; D Pickering
Journal:  Br Med J       Date:  1969-05-24

8.  Sensitivity of Nocardia to trimethoprim and sulphonamides in vitro.

Authors:  W A Black; D A McNellis
Journal:  J Clin Pathol       Date:  1970-07       Impact factor: 3.411

9.  Trimethoprim resistance determined by R factors.

Authors:  M P Fleming; N Datta; R N Grüneberg
Journal:  Br Med J       Date:  1972-03-18

Review 10.  Chemotherapy of typhoid fever: a review of literature.

Authors:  C Herzog
Journal:  Infection       Date:  1976       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.